^
Association details:
| Biomarker: | BCL2 overexpression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo
Published date:
08/28/2021
Excerpt:
Significant increases in mRNA and protein expression levels of Bcl-2 were found in PC-9-Br compared with parental PC-9 (PC-9-P)...A remarkable synergistic effect between EGFR-TKI gefitinib and Bcl-2 inhibitors ABT-263...or ABT-199...to overcome acquired resistance to gefitinib...in PC-9-Br was observed in MTT assays....In conclusion, our study demonstrated gefitinib + ABT263/ABT199, afatinib, and AZD9291 have clinical potential to treat LCBM.
DOI:
10.1007/s00204-021-03147-4
